EUVIMEDEUVIMED entdecken
Crossref

HMGB3 Contributes to Anti‐PD‐1 Resistance by Inhibiting IFN‐γ‐Driven Ferroptosis in TNBC

Bo Luo, Hongmei Zheng, Gai Liang, Yan Luo, Qu Zhang, Xiang Li

Molecular Carcinogenesis · 2025

DOI: 10.1002/mc.23861 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Bo Luo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Ferroptosis, Triple Negative Breast Neoplasms, Interferon-gamma, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: This study was supported by grants from the Hubei Cancer Hospital Biomedical Center Research Fund (Grant No. 2022SWX18)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our previous studies showed HMGB3 expression may correlate with immunotherapy efficacy in breast cancer patients. Here, we investigated whether HMGB3 overexpression has an impact on anti‐PD‐1 therapy in triple‐negative breast cancer (TNBC) and its molecular mechanisms. Animal models were established to observe the effect of HMGB3 on sensitivity to anti‐PD‐1 treatment. Correlation of HMGB3 expression and ferroptosis preventive proteins in TNBC patients' tissues with anti‐PD‐1 therapy efficacy was analyzed. The impact of HMGB3 on IFN‐γ (Interferon‐gamma) inhibitory effects and signaling was examined in human TNBC cells where HMGB3 expression was knocked down using siRNA. Moreover, TNBC cells stably transfected with lentiviral vectors containing cDNA of HMGB3 were also used to confirm the effect of overexpression of HMGB3 on IFN‐γ inhibitory effect and signaling. Effect of HMGB3 on IFN‐γ‐driven ferroptosis and ferroptosis‐associated protein expression were also investigated. Correlation of HMGB3 and IRF1 and GPX4 expression in patient's cancer tissue were also investigated. Our results demonstrated that HMGB3 expression contributes to resistance to anti‐PD‐1 therapy in vivo. HMGB3 expression correlated with treatment efficacy of immunotherapy and survival in TNBC patients. HMGB3 silence decreased resistance of breast cancer cells to IFN‐γ cytotoxic effect, while HMGB3 overexpression increased resistance of these cancer cells. HMGB3 silence increased STAT1 phosphorylation and IRF1 expression upon IFN‐γ treatment compared with control. Overexpression of HMGB3 inhibited STAT1 phosphorylation and IFN‐γ signaling in TNBC cells. Moreover, HMGB3 also increased STAT3 activation and had an effect of interaction between STAT1 and STAT3. HMGB3 overexpression decreased IFN‐γ‐driven ferroptosis in TNBC cells. HMGB3 increased ferroptosis‐inhibitory proteins (SLC7A11, GPX4, and SLC3A2) expression in TNBC cells. Ferroptosis inhibition recovers resistance to anti‐PD‐1 therapy in vivo. Immunohistochemistry showed HMGB3 expression correlated with ferroptosis‐associated proteins and IRF1 expression in breast cancer tissue. HMGB3 contributes to anti‐PD‐1 resistance by inhibiting IFN‐γ‐driven ferroptosis in TNBC which suggested HMGB3 is a potential co‐target with anti‐PD‐1 therapy for TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisTriple Negative Breast NeoplasmsInterferon-gammaDrug Resistance, NeoplasmHMGB3 ProteinProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsHumansAnimalsFemaleMiceCell Line, TumorGene Expression Regulation, NeoplasticXenograft Model Antitumor AssaysSignal TransductionSTAT1 Transcription FactorInterferon Regulatory Factor-1

Stichwörter der Autor:innen

HMGB3IFN‐γbreast cancerferroptosisimmunotherapy

Substanzen

Interferon-gammaHMGB3 ProteinProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, humanSTAT1 Transcription FactorInterferon Regulatory Factor-1IRF1 protein, human

Autor:innen und Institutionen

  • Department of Radiotherapy Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan, Hubei, China.
  • Wuhan Clinical Research Center for Breast Cancer, Wuhan, Hubei, China.
  • Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Förderung

  • This study was supported by grants from the Hubei Cancer Hospital Biomedical Center Research Fund (Grant No. 2022SWX18).

Zitieren

APA

Luo, B., Zheng, H., Liang, G., Luo, Y., Zhang, Q., & Li, X. (2025). HMGB3 Contributes to Anti‐PD‐1 Resistance by Inhibiting IFN‐γ‐Driven Ferroptosis in TNBC. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23861

Vancouver

Luo B, Zheng H, Liang G, Luo Y, Zhang Q, Li X. HMGB3 Contributes to Anti‐PD‐1 Resistance by Inhibiting IFN‐γ‐Driven Ferroptosis in TNBC. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23861

BibTeX
@article{Luo2025,
  author = {Luo, Bo and Zheng, Hongmei and Liang, Gai and Luo, Yan and Zhang, Qu and Li, Xiang},
  title = {HMGB3 Contributes to Anti‐PD‐1 Resistance by Inhibiting IFN‐γ‐Driven Ferroptosis in TNBC},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  doi = {10.1002/mc.23861}
}
Kostenlos starten →